Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M18,123Revenue $M512Net Margin (%)-9.5Z-Score9.8
Enterprise Value $M18,211EPS $-0.3Operating Margin %-0.9F-Score4
P/E(ttm))0Cash Flow Per Share $-1.3Pre-tax Margin (%)-9.5Higher ROA y-yY
Price/Book010-y EBITDA Growth Rate %0Quick Ratio3.2Cash flow > EarningsY
Price/Sales34.65-y EBITDA Growth Rate %0Current Ratio3.2Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-6.8Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M172ROI % (ttm)-131.6Gross Margin Increase y-yN

Gurus Latest Trades with INCY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
INCYMariko Gordon 2014-12-31 Sold Out -0.05%$45.6 - $78.89
($65.73)
$ 105.5138%Sold Out0
INCYKen Fisher 2014-12-31 Add$45.6 - $78.89
($65.29)
$ 105.5138%Add 97.08%14,870
INCYVanguard Health Care Fund 2014-09-30 Add0.07%$45.35 - $56.59
($50.13)
$ 105.5152%Add 6.08%10,174,343
INCYMariko Gordon 2014-09-30 Add$45.35 - $56.59
($50.13)
$ 105.5152%Add 6.55%25,283
INCYKen Fisher 2014-09-30 Reduce$45.35 - $55.78
($50.07)
$ 105.5153%Reduce -38.28%7,545
INCYVanguard Health Care Fund 2014-06-30 Add0.68%$43.1 - $56.39
($50.98)
$ 105.5152%Add 95.66%9,591,143
INCYMariko Gordon 2014-06-30 Reduce-0.19%$43.1 - $56.39
($50.98)
$ 105.5152%Reduce -78.93%23,728
INCYGeorge Soros 2014-06-30 Sold Out -0.01%$43.1 - $56.39
($50.98)
$ 105.5152%Sold Out0
INCYKen Fisher 2014-06-30 Buy $43.1 - $56.39
($50.98)
$ 105.5152%New holding12,225
INCYVanguard Health Care Fund 2014-03-31 Add0.07%$49.94 - $68.83
($62.06)
$ 105.5141%Add 9.97%4,901,968
INCYMariko Gordon 2014-03-31 Reduce-0.03%$49.94 - $68.83
($62.06)
$ 105.5141%Reduce -12.67%112,623
INCYGeorge Soros 2014-03-31 Buy 0.01%$49.94 - $68.83
($61.83)
$ 105.5141%New holding23,200
INCYVanguard Health Care Fund 2013-12-31 Add0.1%$34.71 - $51.34
($43.56)
$ 105.5159%Add 17.08%4,457,643
INCYMariko Gordon 2013-12-31 Reduce-0.06%$34.71 - $51.34
($43.45)
$ 105.5159%Reduce -20.50%128,959
INCYVanguard Health Care Fund 2013-06-30 Add0.05%$19.07 - $24.49
($21.85)
$ 105.5179%Add 21.52%3,807,443
INCYVanguard Health Care Fund 2013-03-31 Buy 0.29%$16.61 - $24.95
($20.44)
$ 105.5181%New holding3,133,100
INCYGeorge Soros 2011-03-31 Sold Out $13.37 - $16.56
($14.71)
$ 105.5186%Sold Out0
INCYGeorge Soros 2010-12-31 Buy $14.51 - $17.17
($16.13)
$ 105.5185%New holding15,000
INCYBill Gates 2009-06-30 Sold Out -0.01%$2.06 - $3.84
($2.79)
$ 105.5197%Sold Out0
INCYJean-Marie Eveillard 2009-03-31 Sold Out $2.14 - $3.78
($2.9)
$ 105.5197%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

INCY is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


INCY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Wenqing YaoEVP, Discovery Medicinal and P 2015-04-13Sell23,000$95.185.37view
SWAIN PAULA JEVP, Human Resources 2015-04-13Sell16,469$96.294.15view
Wenqing YaoEVP, Discovery Medicinal and P 2015-04-07Sell20,031$90.1311.27view
Levy Richard SEVP, Chief Drug Dev Officer 2015-04-06Sell25,000$88.7712.98view
Huber Reid MEVP, Chief Scientific Officer 2015-03-30Sell34,263$93.667.08view
Chardonnet LaurentVice President and Treasurer 2015-03-30Sell113,776$93.647.1view
SWAIN PAULA JEVP, Human Resources 2015-03-16Sell17,500$89.9711.47view
Siegel Eric H.EVP, General Counsel 2015-03-12Sell2,222$89.7211.78view
ARIKO BARRY ADirector 2015-03-12Sell80,000$89.2712.34view
Levy Richard SEVP, Chief Drug Dev Officer 2015-03-06Sell25,000$89.9111.54view

Press Releases about INCY :

Quarterly/Annual Reports about INCY:

News about INCY:

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc. Jun 09 2014 
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN Jun 08 2014 
Weekly Insider Sells Highlight: CPN, INCY, GPK, CODE Feb 24 2014 
Weekly CFO Sells Highlight: Pandora Media Inc, Incyte Corp Ltd, Google Inc, American Airlines Group Feb 24 2014 
Weekly CEO Sells Highlight: ExOne Co, Atmel Corporation, Best Buy and Incyte Corp Ltd. Sep 22 2013 
Weekly CFO Sells Highlight: INTU, INCY, RLD, MIDD, XONE Sep 16 2013 
Weekly CEO Sells Highlight: DIS, LMT, INCY, ADBE May 14 2012 
Weekly Top Insider Buys: VTR, INCY, FULT, HMA, CMC Jan 23 2012 
04 stocks with insider buying of more than $1.5 million since beginning of 2012 Jan 23 2012 
Weekly CFO Sales Highlight: EPIQ, INCY, AVB, JOSB, PCS, FLO Jun 12 2011 

More From Other Websites
AbbVie: Strong Data, Once Daily Dose 'Necessary to Ensure Strong Commercial Success' Apr 15 2015
Incyte to Establish European Headquarters in Geneva, Switzerland Apr 14 2015
Incyte to Report First Quarter Financial Results on April 30 Apr 14 2015
Incyte to Report First Quarter Financial Results on April 30 Apr 14 2015
Incyte to Establish European Headquarters in Geneva, Switzerland Apr 14 2015
INCYTE CORP Files SEC form 8-K, Change in Directors or Principal Officers Apr 13 2015
Novartis' Jakavi Gets EC Approval for Polycythemia Vera - Analyst Blog Mar 18 2015
Jakavi® (ruxolitinib) Receives European Commission Approval as First Targeted Therapy for Patients... Mar 17 2015
Jakavi® (ruxolitinib) Receives European Commission Approval as First Targeted Therapy for Patients... Mar 17 2015
Baker Bros. Advisors Hits the Jackpot with Pharmacyclics Inc (PCYC) Sale; Incyte Corporation (INCY)... Mar 05 2015
Biotech Incyte has both sales and pipeline Mar 04 2015
Incyte Appoints Steven H. Stein, MD as Chief Medical Officer Mar 02 2015
Incyte Appoints Steven H. Stein, MD as Chief Medical Officer Mar 02 2015
Incyte Sponsors First Observational Study Designed to Understand the Impact of Polycythemia Vera –... Feb 26 2015
Incyte Sponsors First Observational Study Designed to Understand the Impact of Polycythemia Vera –... Feb 26 2015
Eli Lilly's BIL Filing Delayed, Baricitinib Scores in Phase III - Analyst Blog Feb 24 2015
Baricitinib Superior to Placebo in Reducing Rheumatoid Arthritis Disease Activity in Second Phase 3... Feb 23 2015
Baricitinib Superior to Placebo in Reducing Rheumatoid Arthritis Disease Activity in Second Phase 3... Feb 23 2015
INCYTE CORP Financials Feb 21 2015
INCYTE CORP Files SEC form 8-K, Other Events Feb 20 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK